Abstract: A monohull vessel for laying a pipeline includes tensioners 13 disposed along a Pipelaying path P. The pipelaying path P includes an upstream portion that is substantially horizontal and at least 10 m above the center of rolling R of the vessel and, towards a stern end of the vessel hull, a downstream portion that is downwardly inclined and, in use, enters the water at a location inboard of the stern end of the vessel hull 1.

Abstract: The disclosure describes techniques for delivering vagal stimulation to decrease the ventricular rate response during an atrial tachyarrhythmia, such as atrial fibrillation. Decreasing the ventricular rate response during an atrial tachyarrhythmia may facilitate increased ventricular pacing for cardiac resynchronization therapy (CRT), and may also reduce the likelihood of inappropriately detecting a ventricular tachyarrhythmia during the atrial tachyarrhythmia. Furthermore, the vagal stimulation may augment vagal tone, which may facilitate long term left ventricular reverse remodeling and decrease atrial and ventricular arrhythmic burden in heart failure patients. An example system that delivers CRT comprises a processor that detects an atrial tachyarrhythmia in one or more atria of the heart, and monitors at least one of a ventricular rate or degree of ventricular pacing subsequent to the detected atrial arrhythmia.

Abstract: A method of laying a pipeline on the bed of a body of water includes constructing, on a laying vessel, a pipeline having pipe sections of a designated or given thickness, and thicker pipe sections distributed along the pipeline; moving the laying vessel forward and laying the pipeline in the body of water as the pipeline is constructed; and propelling a train, configured to plug the pipeline, in steps inside the pipeline laid on the bed of the body of water; the step travel of the train being related to the position of the thicker pipe sections, and to the touchdown point of the pipeline on the bed of the body of water.

Abstract: A pipe-laying vessel including a pipe-laying tower extending upwardly from the vessel, the tower including a first lower section extending upwardly from a proximal end to a distal end above the main deck of the vessel, and a second upper section movably mounted on the first lower section, and the tower having a first pipe-laying configuration for laying pipeline P in which the upper section is positioned above the lower section and pipe is passed from the upper section to the lower section when, in use, it is being laid, and a second stowed configuration in which the second upper section is moved relative to the lower section and the overall height of the tower is reduced.

Abstract: A pipe-laying vessel including a pipe-laying tower extending upwardly from the vessel, the vessel including a welding station for joining a new pipestring to an end of the pipeline held by the tower, a clamp assembly on the tower for engaging a pipestring with a lower end adjacent to the end of the pipeline held by the tower and with the pipestring extending upwardly from its lower end alongside the tower, wherein the clamp assembly includes a pipestring clamp that serves both the function of a transfer clamp for transferring the pipestring from a position alongside the tower but displaced from the pipe-laying path to a position approximately aligned with the pipe-laying path, and the function of a line-up clamp for lining up the pipestring with the end of the pipeline.

Abstract: The disclosure describes techniques for delivering vagal stimulation to decrease the ventricular rate response during an atrial tachyarrhythmia, such as atrial fibrillation. Decreasing the ventricular rate response during an atrial tachyarrhythmia may facilitate increased ventricular pacing for cardiac resynchronization therapy (CRT), and may also reduce the likelihood of inappropriately detecting a ventricular tachyarrhythmia during the atrial tachyarrhythmia. Furthermore, the vagal stimulation may augment vagal tone, which may facilitate long term left ventricular reverse remodeling and decrease atrial and ventricular arrhythmic burden in heart failure patients. An example system that delivers CRT comprises a processor that detects an atrial tachyarrhythmia in one or more atria of the heart, and monitors at least one of a ventricular rate or degree of ventricular pacing subsequent to the detected atrial arrhythmia.

Abstract: The disclosure describes techniques for delivering vagal stimulation to decrease the ventricular rate response during an atrial tachyarrhythmia, such as atrial fibrillation. Decreasing the ventricular rate response during an atrial tachyarrhythmia may facilitate increased ventricular pacing for cardiac resynchronization therapy (CRT), and may also reduce the likelihood of inappropriately detecting a ventricular tachyarrhythmia during the atrial tachyarrhythmia. Furthermore, the vagal stimulation may augment vagal tone, which may facilitate long term left ventricular reverse remodeling and decrease atrial and ventricular arrhythmic burden in heart failure patients. An example system that delivers CRT comprises a processor that detects an atrial tachyarrhythmia in one or more atria of the heart, and monitors at least one of a ventricular rate or degree of ventricular pacing subsequent to the detected atrial arrhythmia.

Abstract: A laying ramp for laying a pipeline on the bed of a body of water can include an elongated frame having a first and second end; connecting members connecting the first end of the elongated frame to a vessel; at least one guide device fitted to the elongated frame to guide the pipeline along the elongated frame; and a support assembly, which has at least one undercarriage to roll along the bed of the body of water and support the second end of the elongated frame.

Abstract: A method of detecting stall in an axial fan through acoustical measurements in air the air flow, includes measuring the sound emanating from the flow adjacent the fan, preparing a visual representation of the sound, comparing the visual representation with a library of fixed visual representations derived from a plurality of tests representative of the performance of the fan under a range of operating parameters, selecting the fixed visual representation most closely matching the visual representation of the said sound, and deriving a control signal from the selected fixed visual representation. The visual representations are formed by a symmetrised dot pattern (SDP) technique.

Abstract: The disclosure describes techniques for delivering vagal stimulation to decrease the ventricular rate response during an atrial tachyarrhythmia, such as atrial fibrillation. Decreasing the ventricular rate response during an atrial tachyarrhythmia may facilitate increased ventricular pacing for cardiac resynchronization therapy (CRT), and may also reduce the likelihood of inappropriately detecting a ventricular tachyarrhythmia during the atrial tachyarrhythmia. Furthermore, the vagal stimulation may augment vagal tone, which may facilitate long term left ventricular reverse remodeling and decrease atrial and ventricular arrhythmic burden in heart failure patients. An example system that delivers CRT comprises a processor that detects an atrial tachyarrhythmia in one or more atria of the heart, and monitors at least one of a ventricular rate or degree of ventricular pacing subsequent to the detected atrial arrhythmia.

Abstract: A monohull vessel for laying a pipeline includes tensioners 13 disposed along a Pipelaying path P. The pipelaying path P includes an upstream portion that is substantially horizontal and at least 10 m above the centre of rolling R of the vessel and, towards a stern end of the vessel hull, a downstream portion that is downwardly inclined and, in use, enters the water at a location inboard of the stern end of the vessel hull 1.

Abstract: The present invention provides novel crystalline polymorph forms of atomoxetine hydrochloride denominated Forms B and C and methods for their preparation, as well as methods for the preparation of Form A. The present invention provides pharmaceutical compositions that comprise atomoxetine hydrochloride Form B, Form C, or mixtures thereof that can be used to treat attention deficit/hyperactivity disorder.

Abstract: The present invention provides improved processes for the preparation of atomoxetine hydrochloride under reaction conditions that improve reaction yields and facilitate commercial synthesis. In particular, the invention is directed to the synthesis of atomoxetine HCl by adding HCl to a mixture of (R)-(?)-tomoxetine (S)-(+)-mandelate with an organic solvent, with or without a base and water.

Abstract: The invention is directed to levalbuterol HCl Form B and methods of making the same.

Abstract: Provided are processes for the preparation of (R)-SLB.D-DBTA salt and levalbuterol hydrochloride. Also provided are levalbuterol hydrochloride degradation products and processes for preparing them. Pharmaceutical compositions comprising at least one levalbuterol hydrochloride of the invention and at least one pharmaceutically-acceptable excipient are also provided.

Abstract: The present invention provides novel crystalline polymorph forms of atomoxetine hydrochloride denominated Forms B and C and methods for their preparation, as well as methods for the preparation of Form A. The present invention provides pharmaceutical compositions that comprise atomoxetine hydrochloride Form B, Form C, or mixtures thereof that can be used to treat attention deficit/hyperactivity disorder.

Abstract: The present invention provides novel crystalline polymorph forms of atomoxetine hydrochloride denominated Forms B and C and methods for their preparation, as well as methods for the preparation of Form A. The present invention provides pharmaceutical compositions that comprise atomoxetine hydrochloride Form B, Form C, or mixtures thereof that can be used to treat attention deficit/hyperactivity disorder.

Abstract: The invention is directed to processes for making levalbuterol HCl Polymorph A from by suspending or forming a first slurry of (R)-SLB(D)-DBTA in at least a first organic solvent, adding HCl to the suspension or slurry of the solid (R)-SLB.D-DBTA until the (R)-SLB.D-DBTA forms levalbuterol HCl Polymorph A, and isolating the levalbuterol HCl Polymorph A.

Abstract: The present invention provides improved processes for the preparation of atomoxetine hydrochloride under reaction conditions that improve reaction yields and facilitate commercial synthesis. In particular, the invention is directed to the synthesis of atomoxetine HCl by adding HCl to a mixture of (R)-(?)-tomoxetine (S)-(+)-mandelate with an organic solvent, with or without a base and water. In preferred embodiments, the atomoxetine hydrochloride produced is Form A.

Abstract: Provided are processes for the preparation of (R)-SLB.D-DBTA salt and levalbuterol hydrochloride. Also provided are levalbuterol hydrochloride degradation products and processes for preparing them. Pharmaceutical compositions comprising at least one levalbuterol hydrochloride of the invention and at least one pharmaceutically-acceptable excipient are also provided.